We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.
- Authors
Fukushi, Ken; Narita, Takuma; Hatakeyama, Shingo; Yamamoto, Hayato; Tobisawa, Yuki; Yoneyama, Tohru; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Koie, Takuya; Ohyama, Chikara
- Abstract
Objectives To compare toxicity reporting between patients and clinicians in the case of systemic chemotherapy for urothelial carcinoma. Methods Between June 2013 and March 2016, 100 urothelial carcinoma patients received two courses of chemotherapy of gemcitabine plus cisplatin or gemcitabine plus carboplatin, and they were prospectively enrolled in the present study. During chemotherapy, patients answered European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire C30 quality-of-life questionnaires, including four toxicity-related symptoms (appetite loss, nausea, constipation and diarrhea). Clinicians evaluated adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Differences of toxicity reporting were compared between patients and clinicians. Logistic regression analyses were carried out to investigate potential factors for underreporting by clinicians. Results Toxicity underreporting was most frequently for diarrhea (44%), followed by appetite loss (39%), constipation (33%) and nausea (22%). In total, toxicity underreporting was observed in 72% of patients. Background-adjusted logistic regression analyses showed pretreatment quality-of-life items of global, symptomatic scores to be predictors for toxicity underreporting by clinicians. The limitations of the present study included its retrospective nature and small sample size. Conclusions Toxicity underreporting by clinicians is frequent in urothelial carcinoma patients receiving systemic chemotherapy. Pretreatment quality-of-life evaluation is essential not only for quality-of-life evaluation, but also to identify potential individuals at risk for toxicity underreporting.
- Subjects
CANCER chemotherapy; TRANSITIONAL cell carcinoma; APPETITE loss; DIARRHEA; LOGISTIC regression analysis; THERAPEUTICS
- Publication
International Journal of Urology, 2017, Vol 24, Issue 5, p361
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.13318